This week at the world brachytherapy meeting in Barcelona, Spain, the medical technology company IsoRay will demonstrate a number of advances in brachytherapy. A number of activities will be demonstrated at the company’s booth.
The world brachytherapy program is presented by the Groupe Europeen de Curietherapie and the European Society for Therapeutic Radiology and Oncology (GEC-ESTRO), in cooperation with American Brachytherapy Society (ABS), Asociacion Latinoamericana de Terapia Radiante Oncologica (ALATRO), and the Indian and Australasian brachytherapy groups.
According to IsoRay, renowned physicians from major medical institutions will host a series of discussion groups regarding the innovative GliaSite radiation system treatment, which represents a major advance over previous brain cancer treatments.
In addition to demonstrating the GliaSite radiation system, IsoRay's European distributor, Karlheinz Goehl-Medizintechnik Goehl, will be on hand to respond to questions.
IsoRay’s company booth at the conference will also feature slide shows, videos and working demonstrations of the application of mesh with Cesium-131 embedded seeds for use in brain, head and neck, lung, ocular, gynecological and prostate cancers.
GliaSite remains the world's only system that allows doctors to place a specified dosage of liquid radiation in areas where cancer is most likely to remain after surgical brain tumor removal. The specificity of the dosage placement means damage is less likely to occur to healthy brain tissue in contrast to other treatments.
"The international medical community has become increasingly aware of the key advantages GliaSite offers patients battling Glioblastomas and metastasized brain cancers,” said IsoRay CEO Dwight Babcock. “We expect interest in GliaSite to continue to increase as doctors adopt this groundbreaking radiation therapy system."
Babcock noted that he expects international sales to begin in the near term. IsoRay's pioneering brachytherapy treatment, Cesium-131, will share center stage with the GliaSite internal radiation therapy system at the world meeting.
A number of presentations, published in the Brachytherapy Journal of the ABS, will also feature at the event and focus on important findings regarding Cesium-131 brachytherapy.
Edited by
Braden Becker
